# SBC Medical Group Holdings Inc (SBC) Informational only - not investment advice. CIK: 0001930313 SIC: 8011 Services-Offices & Clinics of Doctors of Medicine SIC breadcrumb: [Services](/division/I/) > [SIC Major Group 80](/major-group/80/) > [SIC 8011 Services-Offices & Clinics of Doctors of Medicine](/industry/8011/) Latest 10-K filed: 2026-03-27 SEC page: https://www.sec.gov/edgar/browse/?CIK=1930313 Filing source: https://www.sec.gov/Archives/edgar/data/1930313/000119312526127557/sbc-20251231.htm ## At a glance FY2025 · period end 2025-12-31 · filed 2026-03-27 · accession 0001193125-26-127557 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001930313.json | Metric | Value | FY | Provenance | | --- | ---: | ---: | --- | | Revenue | 173,607,489 USD | 2025 | verified | | Net income | 50,985,613 USD | 2025 | verified | | Assets | 380,447,946 USD | 2025 | verified | | Free cash flow | 23,267,484 USD | 2025 | computed | | Net margin | 29.37% | 2025 | computed | | Operating margin | 38.87% | 2025 | computed | | Revenue YoY | -15.48% | 2025 | computed | | ROE | 20.54% | 2025 | computed | Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity. No market price, no rating, no forecast on this site. Not investment advice. ### Peer percentile fingerprint | Ratio | SBC | Peer median | Percentile | N | | --- | ---: | ---: | ---: | ---: | | Net margin | 29.4% | 3.2% | 100 | 56 | | Operating margin | 38.9% | 5.5% | 100 | 51 | | Revenue growth | -15.5% | 11.8% | 5 | 57 | | FCF margin | 13.4% | 5.4% | 96 | 48 | | ROE | 20.5% | 7.9% | 87 | 53 | | ROA | 13.4% | 2.8% | 96 | 58 | | Liabilities / equity | 0.47 | 1.13 | 28 | 54 | | Current ratio | 3.78 | 1.63 | 82 | 58 | Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 80 SIC Major Group 80, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking. ## Selected Fundamentals | Metric | Value | Unit | FY | Filed | | --- | ---: | --- | ---: | --- | | Revenue | 173607489 | USD | 2025 | 2026-03-27 | | Net income | 50985613 | USD | 2025 | 2026-03-27 | | Assets | 380447946 | USD | 2025 | 2026-03-27 | ## Financials Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-27. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001930313.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts. | Metric | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | | Revenue | | 193,542,423 | 205,415,542 | 173,607,489 | | Net income | | 39,370,036 | 46,614,275 | 50,985,613 | | Operating income | | 70,660,066 | 70,303,710 | 67,486,398 | | Gross profit | | 137,304,038 | 156,050,507 | 127,283,722 | | Diluted EPS | | 0.42 | 0.48 | 0.50 | | Operating cash flow | | 50,670,322 | 20,582,933 | 24,668,496 | | Capital expenditures | | 8,543,351 | 2,564,643 | 1,401,012 | | Share buybacks | | | 0.00 | 4,999,997 | | Assets | 119,942,205 | 258,805,271 | 266,083,154 | 380,447,946 | | Liabilities | 4,591,012 | 114,995,022 | 71,060,996 | 117,143,240 | | Stockholders' equity | -3,358,671 | 142,159,177 | 195,109,157 | 248,282,196 | | Cash and cash equivalents | 485,564 | 103,022,932 | 125,044,092 | 163,773,838 | | Free cash flow | | 42,126,971 | 18,018,290 | 23,267,484 | ### Ratios ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported. | Metric | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | | Net margin | | 20.34% | 22.69% | 29.37% | | Operating margin | | 36.51% | 34.23% | 38.87% | | Return on equity | | 27.69% | 23.89% | 20.54% | | Return on assets | | 15.21% | 17.52% | 13.40% | | Liabilities / equity | | 0.81 | 0.36 | 0.47 | | Current ratio | 1.28 | 1.79 | 3.01 | 3.78 | ## As-reported value updates 6 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period. Ledger: /company/SBC/revisions/ ## Quarterly Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-13. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001930313.json. Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived. | Quarter | End date | Revenue | Net income | Diluted EPS | Method | | --- | --- | ---: | ---: | ---: | --- | | 2023-Q3 | 2023-06-30 | | 196,786 | | reported discrete quarter | | 2023-Q4 | 2023-12-31 | | -365,817 | | derived Q4 = FY annual - nine-month YTD | | 2024-Q1 | 2024-03-31 | | -292,546 | | reported discrete quarter | | 2024-Q2 | 2024-03-31 | | -292,546 | | reported discrete quarter | | 2024-Q3 | 2024-09-30 | 53,084,883 | 2,832,894 | 0.03 | reported discrete quarter | | 2024-Q4 | 2024-12-31 | 44,420,537 | 6,539,221 | | derived Q4 = FY annual - nine-month YTD | | 2025-Q1 | 2025-03-31 | 47,328,701 | 21,502,446 | 0.21 | reported discrete quarter | | 2025-Q2 | 2025-06-30 | 43,358,847 | 2,458,240 | 0.02 | reported discrete quarter | | 2025-Q3 | 2025-09-30 | 43,353,235 | 12,824,636 | 0.12 | reported discrete quarter | | 2025-Q4 | 2025-12-31 | 39,566,706 | 14,200,291 | | derived Q4 = FY annual - nine-month YTD | | 2026-Q1 | 2026-03-31 | 43,060,562 | 11,308,071 | 0.11 | reported discrete quarter | | 2026-Q2 | 2026-06-30 | 49,188,068 | 10,692,822 | 0.10 | reported discrete quarter | ## Filed narrative (10-K & 10-Q) ## Business Verbatim Item 1 Business section from SBC's latest 10-K: [/company/SBC/business/](/company/SBC/business/). ## Risk Factors Verbatim Item 1A Risk Factors from SBC's latest 10-K: [/company/SBC/risk-factors/](/company/SBC/risk-factors/). ## Latest quarter (10-Q) Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1930313/000119312526347843/sbc-20260630.htm Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high Filing date: 2026-08-13 Report date: 2026-06-30 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis summarize the significant factors affecting our operating results, financial condition, liquidity, and cash flows for the periods presented below. The following discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report. The forward-looking statements contained herein are based on management’s judgment, assumptions made by management and information currently available to it. Actual results could differ materially from those discussed or implied in the forward-looking statements as a result of various factors, including those described elsewhere in this Quarterly Report and the Annual Report, particularly in “Part II, Item 1A. Risk Factors” of this Quarterly Report, “Part I, Item 1A. Risk Factors” of the Annual Report and the section entitled “Cautionary Note Regarding Forward-Looking Statements” herein. Unless the context otherwise requires, any reference in this section of this Quarterly Report to the “Company,” “SBC,” “we,” “us” or “our” refers to Legacy SBC (defined below) and its consolidated subsidiaries and variable interest entity (“VIE”), prior to the consummation of the Business Combination and to SBC Medical Group Holdings Incorporated, together with its consolidated subsidiaries and its VIE (prior to its deconsolidation), following the Business Combination. Overview SBC Medical Group, Inc. (formerly known as SBC Medical Group Holdings Incorporated), a Delaware corporation and subsidiary of the Company (“Legacy SBC”), is a management company headquartered in Irvine, California and Tokyo, Japan, that provides management services to cosmetic treatment centers mainly in Japan. On September 17, 2024, Legacy SBC consummated its going-public business combination with Pono Capital Two, Inc. (“Business Combination”). In connection with the closing of the Business Combination, Pono Capital Two, Inc. changed its name to SBC Medical Group Holdings Incorporated and the Company’s common stock began trading on Nasdaq under the ticker symbol “SBC”. The Company and its subsidiaries are primarily focused on providing comprehensive management services to franchisee clinics. These services include advertising and marketing across various platforms (such as social media networks), staff management (such as recruitment and training), booking and reservation services for franchisee clinic customers. We also support franchisee clinics through assistance with employee housing rentals and facility rentals, leasehold improvement services and design of clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the customer rewards program (customer loyalty point program), and payment tools. Our wholly owned subsidiary, SBC Medical Group Co., Ltd., a Japanese corporation (“SBC Medical Sub”, or “SBC Japan”), is designated as a “medical service corporation”. In Japan, a medical service corporation is a legal entity that provides management services to “medical corporations”. The management services are conducted through franchisor-franchisee contracts and/or service contracts between SBC Medical Sub and the medical corporations (and, where applicable, other entities) that own domestic franchisee treatment centers in Japan. These treatment centers provide services including but are not limited to breast augmentation, liposuction, rejuvenation treatments (including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging), laser skin toning and spot removal, eyes double fold surgery, rhinoplasty, treatment of osmidrosis and hyperhidrosis, hair transplants, gynecological formation treatments, laser hair removal, face line surgeries, cosmetic dental procedures, tattoo removal, lasik eye surgery, lateral canthoplasty, brow lift procedures, androgenetic alopecia treatment, and cheek sagging prevention methods. Separately, we also enter into franchise arrangements with certain independently operated clinics in Japan pursuant to our Partner Doctor Independence Support Program Agreements, which differ in certain respects from our arrangements with the medical corporations and/or general incorporated associations. 1 Table of Contents The Company’s subsidiaries have entered into franchisor-franchisee contracts and service contracts (including business consignment agreements of the same nature) with seven medical corporations, consisting of Medical Corporation Shobikai, Medical Corporation Kowakai, Medical Corporation Nasukai, Medical Corporation Aikeikai, Medical Corporation Jukeikai, Medical Corporation Ritz Cosmetic Surgery and, effective as of June 2025, Medical Corporation Association Furinkai. In addition, the Company has entered into service contracts since September 2023 with Medical Corporation Association Furinkai and Medical Corporation Association Junikai; and in July 2025 with Medical Corporation Misakikai and General Incorporated Association Miotokai, following the acquisition of MB career lounge Co., Ltd. (collectively with the seven franchisee medical corporations, the “Medical Corporations and/or General Incorporated Associations” or “MCs”). All of the Medical Corporations and General Incorporated Associations are deemed to be related parties of the Company since relatives of the CEO of the Company are the members* of general meetings of members** of the Medical Corporations or General Incorporated Associations. The CEO of the Company was previously a member* of the six franchisee Medical Corporations until he ceased being a member* in July 2023. The Company, through SBC Medical Sub, owns equity interests*** of six franchisee medical corporations. Although the Company, through SBC Medical Sub, has an equity interest*** to the rights to receive a distribution of residual assets in proportion to the amount of contribution in certain circumstances as provided in the Japanese Medical Care Act and in the articles of incorporation (except Medical Corporation Association Furinkai, Medical Corporation Association Junikai, Medical Corporation Misakikai and General Incorporated Association Miotokai), the Company or SBC Medical Sub does not have voting control over the corporate actions at general meetings of members** of the Medical Corporations or General Incorporated Associations per the requirements of the Japanese Medical Care Act. * “Members (or shain) of general meeting of members (or shain)” means one of the organs of a Japanese Medical Corporation, and element of general meeting of members (as explained below) of the Medical Corporation. Each member (or shain) of general meeting of members (or shain) has one voting right. ** “General meeting of members (or shain)” means one of the organs of a Japanese Medical Corporation, and the highest decision-making body of the Medical Corporation, of which the main duties include the election and dismissal of directors (or riji) and corporate auditors (or kanji) of the Medical Corporation, and the approval of financial statements and statutory business reports of the Medical Corporation. *** “Equity interest (or mochibun)” means the right to receive distribution of the residual assets of a Japanese Medical Corporation in proportion to the amount of contribution (Article 10.3.3.2 brackets of the Supplementary Provision of the Japanese Medical Care Act.). However, the procedures for an equity interest (or mochibun) holder to exercise and realize the right to receive distribution of the residual assets of the Medical Corporation is more complicated than that of a stock corporation due to the restrictions under the Medical Care Act. Financial Overview For the three months ended June 30, 2026 and 2025, we generated revenues of $49,188,068 and $43,358,847, respectively, and we reported net income attributable to SBC Medical Group Holdings Incorporated of $10,692,822 and $2,458,240, respectively. For the six months ended June 30, 2026 and 2025, we generated revenues of $92,248,630 and $90,687,548, respectively, and we reported net income attributable to SBC Medical Group Holdings Incorporated of $22,000,893 and $23,960,686, respectively, and cash flows provided by (used in) operating activities of $31,741,248 and $(6,411,168), respectively. As of June 30, 2026, we had retained earnings of $262,449,513. Our primary mission is to provide high-quality comprehensive management services to the MCs and expand our “Shonan Beauty Clinic” brand. We plan to achieve the mission by maintaining and strengthening our market position and brand in the cosmetic medical treatment management market in Japan, Vietnam and Singapore, and by growing our presence globally. Further information regarding our business is provided in “Part I, Item 1. Business” of our Annual Report. Results of Operations Comparison of Results of Operations for the Three Months Ended June 30, 2026 and 2025 Because we acquired control of Waqoo, Inc. (“Waqoo”) on December 19, 2025 and consolidated the financial information of Waqoo and its subsidiary on a three-month reporting lag, our consolidated results for the three months ended June 30, 2026 include Waqoo’s results of operations for the period from January 1, 2026 to March 31, 2026. For comparative purposes, the 2025 segment amounts presented in the tables below relate entirely to the SBC Core Segment, as Waqoo was not consolidated during those periods. 2 Table of Contents The following table summarizes our results of operations as reflected in our unaudited consolidated statements of operations and comprehensive income for the three months ended June 30, 2026 and 2025, and presents information regarding amounts and percentage changes during those periods. [Excerpt truncated for page length; source filing is linked above.] ## Latest 10-K MD&A (excerpt) Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1930313/000119312526127557/sbc-20251231.htm Complete FY 2025 MD&A: /company/SBC/mda/fy2025/ Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high Filing date: 2026-03-27 Report date: 2025-12-31 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis summarize the significant factors affecting our operating results, financial condition, liquidity, and cash flows for the periods presented below. The following discussion and analysis should be read in conjunction with the consolidated financial statements and related notes included elsewhere in this Annual Report. The forward-looking statements contained herein are based on management’s judgment, assumptions made by management and information currently available to it. Actual results could differ materially from those discussed or implied in the forward-looking statements as a result of various factors, including those described below and elsewhere in this Annual Report, particularly in “Part I, Item 1A. Risk Factors” and the section entitled “Cautionary Note Regarding Forward-Looking Statements.” Unless the context otherwise requires, any reference in this section of this Annual Report to the “Company,” “SBC,” “we,” “us” or “our” refers to Legacy SBC and its consolidated subsidiaries and variable interest entity (“VIE”), prior to the consummation of the Business Combination and to SBC Medical Group Holdings Incorporated, the Combined Entity and its consolidated subsidiaries and VIE following the Business Combination. Overview SBC Medical Group, Inc. (formerly known as SBC Medical Group Holdings Incorporated), a Delaware corporation and subsidiary of the Company (“Legacy SBC”) is a management company headquartered in Irvine, California and Tokyo, Japan, that provides management services to cosmetic treatment centers mainly in Japan. On September 17, 2024, Legacy SBC consummated its going-public business combination with Pono Capital Two, Inc. (“Business Combination”). In connection with the closing of the Business Combination, Pono Capital Two, Inc. changed its name to SBC Medical Group Holdings Incorporated and the Company’s common stock began trading on Nasdaq under the ticker symbol “SBC”. The Company and its subsidiaries are primarily focused on providing comprehensive management services to franchisee clinics. These services include advertising and marketing across various platforms (such as social media networks), staff management (such as recruitment and training), booking and reservation services for franchisee clinic customers. We also support franchisee clinics through assistance with employee housing rentals and facility rentals, leasehold improvement services and design of clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the customer rewards program (customer loyalty point program), and payment tools. Our wholly owned subsidiary, SBC Medical Group Co., Ltd., a Japanese corporation (“SBC Medical Sub”, or “SBC Japan”), is designated as a “medical service corporation”. In Japan, a medical service corporation is a legal entity that provides management services to “medical corporations”. The management services are conducted through franchisor-franchisee contracts and/or service contracts between SBC Medical Sub and the medical corporations (and, where applicable, other entities) that own domestic franchisee treatment centers in Japan. These treatment centers provide services including but are not limited to breast augmentation, liposuction, rejuvenation treatments (including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging), laser skin toning and spot removal, eyes double fold surgery, rhinoplasty, treatment of osmidrosis and hyperhidrosis, hair transplants, gynecological formation treatments, laser hair removal, face line surgeries, cosmetic dental procedures, tattoo removal, lasik eye surgery, lateral canthoplasty, brow lift procedures, androgenetic alopecia treatment, and cheek sagging prevention methods. Separately, we also enter into franchise arrangements with certain independently operated clinics in Japan pursuant to our Partner Doctor Independence Support Program Agreements, which differ in certain respects from our arrangements with the medical corporations and/or general incorporated associations. The Company’s subsidiaries have entered into franchisor-franchisee contracts and service contracts with seven medical corporations, consisting of Medical Corporation Shobikai, Medical Corporation Kowakai, Medical Corporation Nasukai, Medical Corporation Aikeikai, Medical Corporation Jukeikai, Medical Corporation Ritz Cosmetic Surgery and, effective as of June 2025, Medical Corporation Association Furinkai. In addition, the Company has entered into service contracts since September 2023 with Medical Corporation Association Furinkai and Medical Corporation Association Junikai; and in July 2025 with Medical Corporation Misakikai and General Incorporated Association Miotokai, following the acquisition of MB career lounge Co., Ltd. (collectively with the seven franchisee medical corporations, the “Medical Corporations and/or General Incorporated Associations” or “MCs”). All of the Medical Corporations and General Incorporated Associations are deemed to be related parties of the Company since relatives of the CEO of the Company are the members* of general meetings of members** of the Medical Corporations or General Incorporated Associations. The CEO of the Company was previously a member* of the six franchisee Medical Corporations until he ceased being a member* in July 2023. The Company, through SBC Medical Sub, owns equity interests*** of six franchisee medical corporations. Although the Company, through SBC Medical Sub, has an equity interest*** to the rights to receive a distribution of residual assets in proportion to the amount of contribution in certain circumstances as provided in the Japanese Medical Care Act and in the articles of incorporation (except Medical Corporation Association Furinkai, Medical Corporation Association Junikai, Medical Corporation Misakikai and General Incorporated Association Miotokai), the Company or SBC Medical Sub does not have voting control over the corporate actions at general meetings of members** of the Medical Corporations or General Incorporated Associations per the requirements of the Japanese Medical Care Act. 106 Table of Contents * “Members (or shain) of general meeting of members (or shain)” means one of the organs of a Japanese Medical Corporation, and element of general meeting of members (as explained below) of the Medical Corporation. Each member (or shain) of general meeting of members (or shain) has one voting right. ** “General meeting of members (or shain)” means one of the organs of a Japanese Medical Corporation, and the highest decision-making body of the Medical Corporation, of which the main duties include the election and dismissal of directors (or riji) and corporate auditors (or kanji) of the Medical Corporation, and the approval of financial statements and statutory business reports of the Medical Corporation. *** “Equity interest (or mochibun)” means the right to receive distribution of the residual assets of a Japanese Medical Corporation in proportion to the amount of contribution (Article 10.3.3.2 brackets of the Supplementary Provision of the Japanese Medical Care Act.). However, the procedures for an equity interest (or mochibun) holder to exercise and realize the right to receive distribution of the residual assets of the Medical Corporation is more complicated than that of a stock corporation due to the restrictions under the Medical Care Act. Financial Overview For the years ended December 31, 2025 and 2024, we generated revenues of $173,607,489 and $205,415,542, respectively, we reported net income attributable to SBC Medical Group Holdings Incorporated of $50,985,613 and $46,614,275, respectively, and cash flows provided by operating activities of $24,668,496 and $20,582,933, respectively. As of December 31, 2025, we had retained earnings of $240,448,620. Our primary mission is to provide quality comprehensive management services to the MCs and expand our “Shonan Beauty Clinic” brand. We plan to achieve the mission by maintaining and strengthening our market position and brand in the cosmetic medical treatment management market in Japan, Vietnam and Singapore, and by growing our presence globally. Further information regarding our business is provided in “Part I, Item 1. Business” of this Annual Report. Results of Operations Comparison of Results of Operations for the Years Ended December 31, 2025 and 2024 Because we acquired control of Waqoo, Inc. ("Waqoo") on December 19, 2025 and consolidated the financial information of Waqoo and its subsidiary on a three-month reporting lag, Waqoo’s results of operations did not impact our consolidated results for the year ended December 31, 2025. The following table summarizes our operating income as reflected in our consolidated statements of operations and comprehensive income for the years ended December 31, 2025 and 2024, and presents information regarding amounts and percentage changes during those periods. [[GREPCENT_TABLE]] [["","","For the Years Ended December 31,"],["","","2025","","","2024","","","Variance"],["","","Amount","","","% of revenue","","","Amount","","","% of revenue","","","Amount","","","%"],["Revenues, net (including net revenues provided to related parties)","","$","173,607,489","","","","100.00","%","","$","205,415,542","","","","100.00","%","","$","(31,808,053",")","","","(15.48",")%"],["Cost of revenues (including cost of revenues from related parties)","","","46,323,767","","","","26.68","%","","","49,365,035","","","","24.03","%","","","(3,041,268",")","","","(6.16",")%"],["Gross profit","","","127,283,722","","","","73.32","%","","","156,050,507","","","","75.97","%","","","(28,766,785",")","","","(18.43",")%"],["Operating expenses (including selling, general and administrative expenses from related parties)","","","59,797,324","","","","34.44","%","","","85,746,797","","","","41.74","%","","","(25,949,473",")","","","(30.26",")%"],["Income from operations","","","67,486,398","","","","38.87","%","","","70,303,710","","","","34.23","%","","","(2,817,312",")","","","(4.01",")%"],["Other income (including other income from related party)","","","14,579,232","","","","8.40","%","","","3,152,107","","","","1.53","%","","","11,427,125","","","","362.52","%"],["Income before income taxes","","","82,065,630","","","","47.27","%","","","73,455,817","","","","35.76","%","","","8,609,813","","","","11.72","%"],["Income tax expense","","","31,020,607","","","","17.87","%","","","26,765,925","","","","13.03","%","","","4,254,682","","","","15.90","%"],["Net income","","","51,045,023","","","","29.40","%","","","46,689,892","","","","22.73","%","","","4,355,131","","","","9.33","%"],["Less: net income attributable to non-controlling interests","","","59,410","","","","0.03","%","","","75,617","","","","0.04","%","","","(16,207",")","","","(21.43",")%"],["Net income attributable to SBC Medical Group Holdings Incorporated","","$","50,985,613","","","","29.37","%","","$","46,614,275","","","","22.69","%","","$","4,371,338","","","","9.38","%"]] [[/GREPCENT_TABLE]] Note: Percentages are calculated as a percentage of total revenue and may not sum due to rounding. 107 Table of Contents Revenues, Net Revenues, net generated from different revenue streams consist of the following: [Excerpt truncated for page length; the complete text is on the linked full-MD&A page.] Read the full FY 2025 MD&A: /company/SBC/mda/fy2025/ All MD&A years: /company/SBC/mda/ ## MD&A history Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page. - [FY 2024 MD&A](/company/SBC/mda/fy2024/): filed 2025-03-28; accession 0001641172-25-001062 (https://www.sec.gov/Archives/edgar/data/1930313/000164117225001062/form10-k.htm) - [FY 2023 MD&A](/company/SBC/mda/fy2023/): filed 2024-03-19; accession 0001493152-24-010402 (https://www.sec.gov/Archives/edgar/data/1930313/000149315224010402/form10-k.htm) - [FY 2022 MD&A](/company/SBC/mda/fy2022/): filed 2023-03-09; accession 0001493152-23-007036 (https://www.sec.gov/Archives/edgar/data/1930313/000149315223007036/form10-k.htm) ## Macro cross-references Indicators mapped to this company's SIC classification (industry 8011 Services-Offices & Clinics of Doctors of Medicine) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim. - [PCE](/indicator/PCE/): Personal Consumption Expenditures - [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product - [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm - [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private - [UNRATE](/indicator/UNRATE/): Unemployment Rate - [DSPIC96](/indicator/DSPIC96/): Real Disposable Personal Income Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/). All macro indicators: /indicators/ ## For LLMs & downloads Markdown twin: /company/SBC.md · JSON record: /company/SBC.json · verified financials: /company/SBC/financials.json / /company/SBC/financials.csv · machine TOC for the whole site: /llms.txt